Identification

Generic Name
Glibornuride
DrugBank Accession Number
DB08962
Background

Glibornuride is a sulfonylurea-type anti-diabetic drug.

Type
Small Molecule
Groups
Investigational, Withdrawn
Structure
Weight
Average: 366.48
Monoisotopic: 366.161328499
Chemical Formula
C18H26N2O4S
Synonyms
  • Glibornurid
  • Glibornurida
  • Glibornuride
  • Glibornuridum
External IDs
  • RO 6-4563

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Abaloparatide.
AbataceptThe metabolism of Glibornuride can be increased when combined with Abatacept.
AbrocitinibThe metabolism of Abrocitinib can be decreased when combined with Glibornuride.
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Glibornuride.
AcebutololThe therapeutic efficacy of Glibornuride can be increased when used in combination with Acebutolol.
AceclofenacThe protein binding of Glibornuride can be decreased when combined with Aceclofenac.
AcemetacinThe protein binding of Glibornuride can be decreased when combined with Acemetacin.
AcenocoumarolThe therapeutic efficacy of Glibornuride can be increased when used in combination with Acenocoumarol.
AcetazolamideThe therapeutic efficacy of Glibornuride can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Glibornuride.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Glutril (Meda Pharma)

Categories

ATC Codes
A10BB04 — Glibornuride
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Bicyclic monoterpenoids
Alternative Parents
Tosyl compounds / Benzenesulfonamides / Aromatic monoterpenoids / Benzenesulfonyl compounds / Sulfonylureas / Organosulfonic acids and derivatives / Aminosulfonyl compounds / Secondary alcohols / Organic carbonic acids and derivatives / Cyclic alcohols and derivatives
show 4 more
Substituents
Alcohol / Aminosulfonyl compound / Aromatic homopolycyclic compound / Aromatic monoterpenoid / Benzenesulfonamide / Benzenesulfonyl group / Benzenoid / Bicyclic monoterpenoid / Bornane monoterpenoid / Carbonic acid derivative
show 18 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
VP83E7434R
CAS number
26944-48-9
InChI Key
RMTYNAPTNBJHQI-LLDVTBCESA-N
InChI
InChI=1S/C18H26N2O4S/c1-11-5-7-12(8-6-11)25(23,24)20-16(22)19-14-13-9-10-18(4,15(14)21)17(13,2)3/h5-8,13-15,21H,9-10H2,1-4H3,(H2,19,20,22)/t13-,14+,15+,18+/m1/s1
IUPAC Name
3-[(1S,2S,3R,4R)-3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]heptan-2-yl]-1-(4-methylbenzenesulfonyl)urea
SMILES
CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[C@@H]1[C@H](O)[C@]2(C)CC[C@H]1C2(C)C

References

Synthesis Reference

U.S. Patent 3,654,357.

General References
Not Available
KEGG Drug
D02427
PubChem Compound
12818200
PubChem Substance
310264926
ChemSpider
16735831
RxNav
102846
ChEBI
135545
ChEMBL
CHEMBL529888
ZINC
ZINC000002012812
Drugs.com
Drugs.com Drug Page
Wikipedia
Glibornuride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)193-195U.S. Patent 3,654,357.
Predicted Properties
PropertyValueSource
Water Solubility0.0635 mg/mLALOGPS
logP2.09ALOGPS
logP2.48ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area95.5 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.73 m3·mol-1ChemAxon
Polarizability38.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da

Drug created at May 30, 2014 17:19 / Updated at February 21, 2021 18:52